二、对外提供财务资助逾期的进展情况 公司近日收到上海君熙生物科技有限公司还款人民币 400 万元。本次还款后， 福君基因尚未偿还的财务资助款项本息合计 24,919,787.84 元。 证券代码：002584 证券简称：西陇科学 公告编号：2023-043 西陇科学股份有限公司 关于转让子公司股权形成对外提供财务资助逾期的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外提供财务资助及逾期概述 西陇科学股份有限公司（以下简称"公司"）因转让福建福君基因生物科技 有限公司（以下简称"福君基因"，现更名为"上海君熙生物科技有限公司"）40.5% 股权，公司持股比例由 51%降至 10.5%，福君基因变为公司的参股公司。公司对 福君基因及其子公司的经营借款被动形成了公司对外提供财务资助，借款金额合 计为人民币 38,108,504.69 元。《西陇科学：关于转让子公司股权后形成对外提 供财务资助的公告》（公告编号：2021-037）于 2021 年 5 月 8 日披露。 截止 2022 年 12 月 31 日，福君基因尚未偿还的财务资助款项本息合计 ...

关于对深圳证券交易所《问询函》的回复公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳证券交易所： 证券代码：002584 证券简称：西陇科学 公告编号：2023-042 西陇科学股份有限公司 贵所于 2023 年 8 月 30 日下发的公司部问询函〔2023〕第 148 号(以下简称"问 询函")已收悉，西陇科学股份有限公司（以下简称：公司或西陇科学）对问询函中 涉及事项逐一进行落实，现将问询函有关问题回复公告如下： 问题 1.2021 年 12 月 7 日，你公司与济南高新实业发展有限公司（以下简称济南 高新实业）、济南高新财金投资有限公司、济南高新盛和发展有限公司签订了《股权 转让协议》，你公司将持有的艾克韦生物 60%的股权以人民币 5.04 亿元的价格转让 给济南高新实业等公司，艾克韦生物 100%股权价格确定为 8.40 亿元。同时，你公司 作出业绩承诺，承诺艾克韦生物 2022、2023、2024 年经审计的税后净利润分别不低 于 4900 万元、6300 万元、7800 万元，业绩承诺期间累计实现净利润不低于 1.9 亿元。 如艾克韦生 ...

证券代码：002584 证券简称：西陇科学 公告编号：2023-041 西陇科学股份有限公司 关于母公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、 担保情况概述 2023 年 4 月 27 日，西陇科学股份有限公司（以下称"西陇科学"或"公司"） 第五届董事会第二十一次会议审议通过了《关于公司及子公司对 2023 年度融资 授信提供担保的议案》。2023 年度，根据公司及子（孙）公司的生产经营和资金 需求情况，公司及子（孙）公司为合并报表范围内公司向金融机构申请融资授信 提供担保，担保额度总计不超过人民币 35 亿元，具体如下： 公司为纳入合并报表范围的子（孙）公司向金融机构申请融资授信提供担保， 总额不超过人民币18.85亿元，其中对最近一期资产负债率小于等于70%的子（孙） 公司担保额度不超人民币 12.75 亿元，对最近一期资产负债率超 70%的子（孙） 公司担保额度不超人民币 6.1 亿元；子（孙）公司为合并范围内其他子（孙）公 司向金融机构申请融资授信提供担保，总额不超过人民币 0.05 亿元，其中对最 近一期资 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 3,670,089,818.71, representing a 39.15% increase compared to CNY 2,637,593,793.18 in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 82.23% to CNY 12,552,517.50 from CNY 70,626,559.37 in the previous year[19]. - Basic earnings per share dropped by 83.33% to CNY 0.02 from CNY 0.12 in the previous year[19]. - The company reported a net cash flow from operating activities of -CNY 297,443,217.51, a 179.92% increase compared to the previous year, primarily due to revenue growth and increased procurement[50]. - The total profit for the first half of 2023 was CNY 15,399,971.89, a decrease of 92.24% from CNY 198,551,859.60 in the same period of 2022[152]. - The company's revenue for the reporting period reached ¥3,670,089,818.71, representing a year-on-year increase of 39.15% due to expanded market demand, particularly for silver nitrate products[49]. - The company's operating costs increased by 44.59% to ¥3,442,789,472.16, reflecting the significant growth in sales of silver nitrate products[49]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,095,488,471.83, an increase of 2.37% from CNY 4,977,416,163.23 at the end of the previous year[19]. - The company's total assets as of June 30, 2023, were CNY 4,100,853,597.41, down from CNY 4,243,427,330.12 at the beginning of the year[146]. - Accounts receivable increased to CNY 1.30 billion, accounting for 25.47% of total assets, up 2.22% from the previous year[54]. - The total liabilities increased to CNY 1,865,439,959.53 from CNY 2,021,950,312.51 at the start of the year, indicating a decrease of about 7.7%[146]. - The company's short-term loans increased to CNY 929.26 million, which is 18.24% of total assets, up 3.17% from the previous year[54]. Research and Development - Research and development expenses decreased by 32.13% to ¥42,752,979.66, influenced by changes in market demand[50]. - The company has accumulated a strong team of researchers and experienced experts, having obtained multiple patents, and will continue to enhance R&D investment and introduce specialized talent[69]. - The company launched new high-end reagents, including vanadium trichloride and new carbon dioxide absorbents, to achieve domestic substitution of high-end reagents[45]. - Research and development expenditures for new products and technologies increased by 8.2% year-on-year, indicating a strong commitment to innovation[161]. Environmental Compliance - The company is subject to environmental protection regulations and has obtained pollution discharge permits valid until August 31, 2023, for its main facilities[80]. - The company has implemented stricter environmental standards in response to increased regulatory scrutiny and has faced operational challenges due to environmental compliance requirements[68]. - The company has achieved a 100% safe disposal rate for hazardous waste, which includes a small amount of organic solvent waste and solid waste containing heavy metals[83]. - The company has established environmental monitoring teams equipped with monitoring instruments to ensure compliance with wastewater and air quality standards[85]. - The company invested a total of 1.229 million yuan in environmental governance and protection during the reporting period, focusing on the maintenance and upgrading of environmental protection facilities[84]. Market Strategy and Expansion - The company plans to enhance its market expansion strategies, focusing on increasing its presence in emerging markets and diversifying its product offerings[162]. - The company is exploring potential mergers and acquisitions to bolster its market position and expand its product portfolio[162]. - The company aims to improve internal management and efficiency to ensure sustained profitability amid competitive pressures[66]. - The company plans to enhance its new product development capabilities and expand into emerging markets to maintain its competitive edge[66]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[4]. - The total number of ordinary shareholders at the end of the reporting period was 64,576[126]. - The total number of shares before the change was 585,216,422, with a total of 26,165,700 shares reduced, resulting in 559,050,722 shares after the change[121]. - Huang Weipeng's shareholding decreased by 38,729,937 shares during the reporting period[126]. Risk Management - The company faced significant risks including macroeconomic downturns and safety production risks[3]. - The company recognizes the risks associated with management complexity due to strategic transformation and will enhance its risk management capabilities[70]. - The company has not experienced any major safety incidents during the reporting period but acknowledges ongoing safety risks associated with its operations[67]. Financial Management - The company reported a significant increase in financial expenses, totaling CNY 27,648,194.23, compared to CNY 20,394,719.42 in the previous year[152]. - The company has not provided guarantees for shareholders, actual controllers, or their related parties during the reporting period[113]. - The company has not reported any significant contracts during the reporting period[116]. - The financial report for the first half of 2023 was not audited[138].

证券代码：002584 证券简称：西陇科学 公告编号：2023-040 西陇科学股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2023 年第一次临时股东大会 2、股东大会的召集人：公司董事会 3、公司第五届董事会第二十三次会议审议通过了《关于提请召开公司 2023 年第一次临时股东大会的议案》，本次股东大会的召开符合《公司法》、《证券法》、 《深圳证券交易所股票上市规则》等有关法律、行政法规、部门规章、规范性文 件以及《公司章程》的规定。 4、会议召开日期和时间： 现场会议召开时间：2023 年 9 月 7 日（星期四）14:30 开始； 网络投票时间：2023 年 9 月 7 日； 权进行股权激励的议案》 上述议案由 2023 年 8 月 21 日公司召开的第五届董事会第二十三次会议和第 五届监事会第十七次会审议通过，《西陇科学：关于通过向参股子公司管理层股 东转让部分股权进行股权激励的公告》与本通知同日在指定信息披露媒体公布。 上述议案涉及影响中小投资 ...

西陇科学股份有限公司独立董事 关于公司第五届董事会第二十三次会议相关事项的独立意见 根据《上市公司独立董事规则》、《深圳证券交易所股票上市规则》及《西陇 科学股份有限公司章程》的有关规定，作为西陇科学股份有限公司（以下简称"公 司"）的独立董事，基于独立、客观判断的原则，就公司第五届董事会第二十三 次会议审议的事项，发表相关意见如下： 公司为纳入合并报表范围的子（孙）公司向金融机构申请融资授信提供担保， 总额不超过人民币18.85亿元，其中对最近一期资产负债率小于等于70%的子（孙） 公司担保额度不超人民币 12.75 亿元，对最近一期资产负债率超 70%的子（孙） 公司担保额度不超人民币 6.1 亿元；子（孙）公司为合并范围内其他子（孙）公 司向金融机构申请融资授信提供担保，总额不超过人民币 0.05 亿元，其中对最 近一期资产负债率小于等于 70%的子（孙）公司担保额度不超人民币 0.05 亿元， 对最近一期资产负债率超 70%的子（孙）公司总担保额度不超人民币 0 亿元；子 （孙）公司为公司向金融机构申请融资授信提供担保，总额不超过人民币 16.1 亿元。 1 截止报告期末，母公司对子公司实际担保余额 ...

证券代码：002584 证券简称：西陇科学 公告编号：2023-039 西陇科学股份有限公司 关于通过向参股子公司管理层股东转让部分股权 进行股权激励的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 西陇科学股份有限公司（以下简称"公司"）于2023年8月21日召开第五届 董事会第二十三次会议、第五届监事会第十七次会议，审议通过了《关于通过 向参股子公司管理层股东转让部分股权进行股权激励的议案》，本议案尚需提 交股东大会审议，现将相关事项公告如下： 一、股权激励方案概述 （一）向参股子公司管理层股东转让部分股权实施股权激励概述 为充分调动山东艾克韦生物技术有限公司（以下简称"艾克韦生物"或"标 的公司"）经营管理团队和核心骨干员工的积极性，将员工利益与艾克韦生物 长远发展紧密结合，促使艾克韦生物管理层积极实现2021年12月7日公司与济南 高新实业发展有限公司、济南高新财金投资有限公司、济南高新盛和发展有限 公司签订的《股权转让协议》中的公司做出的艾克韦生物的业绩承诺，2023年8 月22日公司与济南新丽景生物科技合伙企业（有限合伙）、张国宁签订《股权 ...

证券代码：002584 证券简称：西陇科学 西陇科学股份有限公司 2022 年度业绩说明会 投资者活动记录表 编号：2023-001 | --- | --- | |--------------|----------------------------| | | □分析师会议 | | | □媒体采访 √业绩说明会 | | 投资者关系活 | | | | □新闻发布会 □路演活动 | | 动类别 | | | | □现场参观 □电话会议 | | | （请文字说明其他活动内容） | 参与单位名称 及人员姓名 西陇科学2022年度业绩说明会采用网络远程方式进行，面向全体投资者 时间 2023 年 5 月 11 日 15:00-17:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏 目 主持人：西陇科学 董事长, 总裁：黄少群 公司接待人员 独立董事：曾幸荣 姓名 副总裁、财务总监：王庆东 副总裁、董事会秘书：宗岩 1.公司的会计不够专业，公司有没有认真按照会计流程工作？出错后可 有采取什么补救措施？ 投资者关系活 动主要内容介 答：尊敬的投资者您好，公司一直重视财务管理 ...

Revenue and Profit - The company's revenue for Q1 2023 was ¥1,937,787,670.11, representing a 41.37% increase compared to ¥1,370,689,076.75 in the same period last year[5] - Net profit attributable to shareholders decreased by 87.27% to ¥10,032,938.44 from ¥78,789,802.66 year-on-year[5] - Basic and diluted earnings per share dropped by 84.62% to ¥0.02 from ¥0.13 in the same period last year[5] - The net profit for Q1 2023 was CNY 10,263,465.80, a significant decrease from CNY 78,992,204.84 in Q1 2022, representing a decline of approximately 87%[21] - The total comprehensive income for Q1 2023 was CNY 10,209,000.26, compared to CNY 78,972,725.68 in Q1 2022, indicating a decrease of approximately 87%[22] Cash Flow and Operating Activities - The net cash flow from operating activities was negative at -¥13,769,371.14, a decline of 208.42% compared to ¥12,699,955.54 in the previous year[11] - The cash flow from operating activities showed a net outflow of CNY 13,769,371.14, contrasting with a net inflow of CNY 12,699,955.54 in the same period last year[23] - The net cash flow from financing activities was -CNY 181,091,623.31, compared to -CNY 194,630,992.88 in the same period last year[23] Assets and Liabilities - Total assets increased by 1.61% to ¥5,057,362,009.89 from ¥4,977,416,163.23 at the end of the previous year[5] - The total liabilities increased to CNY 2,731,999,097.66 from CNY 2,661,074,952.66, indicating a rise of 2.6%[18] - The cash and cash equivalents at the end of the first quarter were CNY 746,942,400.01, up from CNY 691,010,308.36 at the beginning of the year, representing an increase of 8.1%[16] - The inventory balance increased to CNY 628,233,968.66 from CNY 508,198,483.15, marking a significant rise of 23.6%[16] - The company experienced a 35.08% decrease in trading financial assets, dropping to ¥194,525,348.36 from ¥299,652,718.51 due to bank wealth management products maturing[8] Costs and Expenses - The company reported a significant increase in main business costs, which rose by 46.57% to ¥1,821,756,346.94 due to higher demand for specialized chemical products[10] - The total operating costs for the first quarter of 2023 were CNY 1,921,849,607.63, up 42.4% from CNY 1,347,511,178.74 in the previous year[19] - The company incurred a total operating profit of CNY 10,843,265.98, a decrease from CNY 88,433,285.73 in the previous year[21] - The company’s research and development expenses for the first quarter were CNY 13,057,237.98, down 19.0% from CNY 16,110,350.98 in the previous year[19] Investment and Financing - Investment income plummeted by 101.31% to -¥951,681.56 from ¥72,607,438.26 in the previous year, primarily impacting net profit[10] - The total cash inflow from investment activities was CNY 300,346,508.14, down from CNY 389,951,398.69 in Q1 2022[23] - Short-term borrowings increased by 32.28% to ¥992,194,390.15 from ¥750,092,603.45, indicating a rise in financing needs[9] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 68,218, with no preferred shareholders[13] - The net profit attributable to the parent company for the first quarter of 2023 was not explicitly stated but can be inferred from the increase in revenue and costs[19]

Financial Performance - The company reported a revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15%[12]. - The net profit attributable to shareholders was RMB 200 million, up 10% compared to the previous year[12]. - The company's operating revenue for 2022 was ¥6,183,208,812.19, a decrease of 14.93% compared to ¥6,837,667,633.82 in 2021[17]. - The net profit attributable to shareholders was ¥88,047,360.97, representing a decline of 52.93% from ¥203,877,034.92 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was ¥7,608,961.07, down 83.00% from ¥57,597,437.75 in 2021[17]. - The net cash flow from operating activities was -¥190,882,683.70, a significant decrease of 151.18% compared to ¥346,617,647.91 in 2021[17]. - The company reported a significant decline in revenue from the medical industry, down 90.44% to ¥18,174,261.12[61]. - The total operating revenue for the reporting period reached ¥6,183,208,812.19, representing a year-on-year increase of 14.93% compared to ¥5,379,903,593.41 in 2021[61]. Investment and R&D - The company plans to invest RMB 300 million in R&D for new product development in the upcoming year, focusing on electronic chemicals and in-vitro diagnostic reagents[12]. - R&D investment increased by 8.21% to ¥128,735,270.36 in 2022, while the proportion of R&D investment to operating revenue decreased to 2.08% from 2.21%[78]. - The company completed four R&D projects that achieved patent certification, resulting in capitalized R&D investments of ¥48,147,847.72, a 405.09% increase from the previous year[78]. - The company is developing high-purity environmentally friendly potassium peroxymonosulfate as part of its new product strategy[78]. - The company has established partnerships with various research institutions to foster innovation in polymer materials[138]. Market Strategy and Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 25% increase in market share in the region by 2025[12]. - The management has provided a performance guidance of 10-15% revenue growth for 2023, driven by new product launches and market expansion efforts[12]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[12]. - The company aims to expand its production scale and market share by focusing on new applications in electronic chemicals and composite reagents for the semiconductor and new energy materials industries[105]. Operational Efficiency and Challenges - The company is facing risks including macroeconomic downturns and environmental compliance, which could impact future performance[3]. - The company implemented a series of management measures to enhance operational efficiency, including a procurement team rotation system and inventory management strategies[58]. - The company is actively pursuing green and low-carbon production methods, aligning with national energy-saving policies[58]. - The company has reported a significant increase in raw material procurement costs, with sodium hydroxide's cost impact on operating expenses at 29.95%, superabsorbent polymer at 10.35%, and glycerol at 31.21%[44]. Governance and Compliance - The company has established a complete and independent financial accounting system, ensuring autonomous financial decision-making[128]. - The company strictly adhered to information disclosure regulations, ensuring timely and accurate communication of significant operational matters to investors[121]. - The company conducted a self-examination and strengthened compliance with securities laws following regulatory measures against its controlling shareholders[143]. - The company received a warning letter from the China Securities Regulatory Commission on November 16, 2022, regarding administrative regulatory measures against its chairman and other executives[142]. Environmental Responsibility - The company has implemented measures to ensure that there are no significant defects in non-financial reporting[176]. - The company has achieved a 100% safe disposal rate for hazardous waste, which includes organic solvents and heavy metal-containing residues[187]. - The company has implemented emergency response plans for environmental incidents, including specific plans for wastewater treatment system failures and gas emission system faults[184]. - The company has maintained a 100% compliance rate for environmental impact assessments and "three simultaneous" systems for all construction projects[193]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,268, with 548 in the parent company and 720 in major subsidiaries[158]. - The company emphasizes the importance of talent development and has conducted annual talent pool updates to ensure a skilled workforce[163]. - The company has established an E-learning platform to promote lifelong learning among employees, covering various topics including marketing and leadership[161]. Customer Engagement and Market Presence - User data indicates a 20% increase in the customer base, reaching 50,000 active users by the end of 2022[12]. - The company has established strategic partnerships with key distributors to enhance sales and customer development, aiming for a win-win cooperation[54]. - The company’s membership and certified buyer numbers on its comprehensive chemical platform, Youliao.com, have continued to rise, reflecting its growing market engagement[50].